Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Zhou, X., Wang, G., Wu, Y., Wu, M., Zhai, X., Tian, C., Prochownik, E
April 29 Product: X4 Pharmaceuticals Xolremdi Indication: WHIM Syndrome The FDA approved X4 Pharmaceuticals Xolremdi Monday as the first targeted treatment for WHIM syndrome, an ultra-rare immunodeficiency disease named for its four characteristics: warts, hypogammaglobulinemia, infections and myelokathexis
Understanding the differences between these medications can help you and your healthcare provider decide which one may be right for you, or if it's time to make a move from one to the other
BioFactors (Oxford, England), 32 (1-4), 199208
US$ 22.66
US$ 24.20
US$ 27.95
US$ 21.14
US$ 23.70
US$ 26.59
US$ 22.82
